A study demonstrates that the combination of EGFR inhibitor erlotinib and IGF-1R inhibitor NVP-AEW541 shows synergistic inhibition than either agent alone in adrenocortical carcinoma 36. The gene discussed is EGFR; the disease is adrenal cortex carcinoma.